image header

Investor Overview

Investor Overview

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.

ALX Oncology


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Sep 21, 2022

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference Read more

Sep 1, 2022

ALX Oncology Announces Upcoming Investor Conference Participation Read more

Aug 15, 2022

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer Read more